Neuronetics

Canaccord Genuity Acted as Sole Bookrunner to Neuronetics, Inc. on its $20.7 Million Public Offering

Canaccord Genuity is pleased to announce that on February 10, 2025, it completed a public offering of common stock for Neuronetics, Inc. (NASDAQ: STIM) (the “Company”). The offering comprised of 9,200,000 shares of common stock, including the exercise in full of the underwriter’s option to purchase additional shares, at a public offering price of $2.25 per share, resulting in gross proceeds of $20.7 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures.

Canaccord Genuity acted as Sole Bookrunner for the offering.
    
Neuronetics develops NeuroStar Advanced Therapy, a non-drug, non-invasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, the Company operates Greenbrook treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder and other mental health disorders.